Overview

A Study of Zanubrutinib Versus Lenalidomide in Participants With Relapsed/Refractory Marginal Zone Lymphoma

Status:
Not yet recruiting

Trial end date:
2028-05-01

Target enrollment:

Participant gender:

Summary

The purpose of the study is to compare the efficacy of zanubrutinib plus rituximab versus lenalidomide plus rituximab in participants with relapsed/refractory marginal zone lymphoma (R/R MZL), as measured by progression-free survival as determined by an independent review committee in accordance with the 2014 modification of the International Working Group on non-Hodgkin lymphoma (NHL) Criteria.

Phase:

Phase 3

Details

Lead Sponsor:

BeiGene

Treatments:

Lenalidomide
Rituximab
Zanubrutinib